argenx (ARGX) Stock: Buy, Sell, or Hold?
ARGX - argenx SE American Depositary Shares
$875.74
-0.02 (0.00%)
âŧ
5d:
+6.91%
30d:
-8.99%
90d:
-1.47%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Oct 22, 2026
0d
Get Alerted When ARGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ARGX is fairly priced but lacks strong directional signals. At -3.1% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ARGX is fairly priced but lacks strong directional signals. At -3.1% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$1732.66
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$1075.85
18.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ARGX is currently trading at $875.74, which is considered fair relative to its 30-day fair value range of $848.52 to $979.42. The stock's valuation (Forward PE: 24.6) is in line with its historical norms (27.0). Remarkably, the market is currently pricing in an annual earnings decline of 3.1% over the next few years. This pessimistic expectation contrasts with the company's recent 95.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ARGX is in a uptrend. The price is approaching resistance at $897.27. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ARGX scores 64/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $1149.65 (+31.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ARGX is in a uptrend. The price is approaching resistance at $897.27. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ARGX scores 64/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $1149.65 (+31.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$848.52 -
$979.42
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (64/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 31.3% below Wall St target ($1149.65)
- WARNING: Composite score 52/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$848.52 -
$979.42
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$798.48
Resistance Level
$897.27
Current Trend
Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.61
Wall Street Target
$1149.65
(+31.3%)
Revenue Growth (YoY)
59.3%
Earnings Growth (YoY)
95.2%
Profit Margin
32.3%
Valuation Discount vs History
-3.1% cheaper
PE vs Historical
24.6 vs 27.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.1%
(market-implied from PE analysis)
1-Year Target
$848.61
(-3%)
2-Year Target
$822.30
(-6%)
3-Year Target
$796.81
(-9%)
3-Yr Target (if PE normalizes)
(PE: 25â27)
$874.31
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 24.6, Growth: 90.6%)
$2955.69
(+238%)
Base:
(SPY PE: 19.9, Growth: 90.6%)
$2385.51
(+172%)
Bear:
(PE: 16.9, Growth: 90.6%)
$2027.68
(+132%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (34x PE), but valuation improves significantly next year (25x PE) as earnings recover.
Trailing PE: 33.92 | Current EPS (TTM): $26.24
Bull Case
$1327.92
(+52%)
Analyst growth 35.6%, PE expands to 37.3
Base Case
$1207.20
(+38%)
Market implied 35.6%, PE stable at 33.9
Bear Case
$605.23
(-31%)
Severe decline -20.0%, PE contracts to 28.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 24.6 to 27.0
Stabilization Target:
$960.93
(+9.7%)
PE Expansion Potential:
+9.7%
Share & Embed Analysis
Last updated: October 23, 2026 2:44 PM ET
Data refreshes hourly during market hours. Next update: 3:44 PM
Data refreshes hourly during market hours. Next update: 3:44 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARGX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 72 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 69 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 56 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
20 analysts |
$17 | 47 HOLD |
|
ACAD
ACADIA Pharmaceuticals IâĻ |
STRONG BUY
20 analysts |
$31 | 61 BUY |
